BioCentury | Feb 1, 2018
Financial News

EdRIP considering split from Rothschild

...Banque. The firm declined to comment. Last May, EdRIP backed idiopathic pulmonary fibrosis (IPF) company Genoa Pharmaceuticals Inc....
BioCentury | May 19, 2017
Finance

Breathe in, cash out

...By installing a proven CEO and ponying up sufficient cash to clear Phase II development, Genoa Pharmaceuticals Inc....
BioCentury | May 17, 2017
Financial News

Genoa's series A brings in $62M

...Pulmonary play Genoa Pharmaceuticals Inc. (Seattle, Wash.) raised $62 million in a series A round on May 15...
...Investment Partners . Also participating were Novo A/S , RiverVest Venture Partners and TPG Biotech. Genoa Pharmaceuticals Inc....
BioCentury | May 15, 2017
Financial News

Genoa's series A brings in $62M

...Pulmonary play Genoa Pharmaceuticals Inc. (Seattle, Wash.) said it raised $62 million in a series A financing led...
BioCentury | Aug 18, 2014
Clinical News

GP-101 regulatory update

...BioCentury, July 14). Pirfenidone is a small molecule inhibitor of proinflammatory cytokines and pro-fibrotic cytokines. Genoa Pharmaceuticals Inc....
BioCentury | Jun 17, 2013
Clinical News

Genoa Pharmaceuticals preclinical data

...rights in South Korea and Taiwan and markets it as Pirespa for IPF in Japan. Genoa Pharmaceuticals Inc....
BioCentury | Mar 21, 2013
Targets & Mechanisms

Understanding fibrosis

...University , ultimately wanted to see studies of pirfenidone plus fasudil. Kolb is collaborating with Genoa Pharmaceuticals Inc....
...Kasei Pharma Corp. , Tokyo, Japan Firestone Institute for Respiratory Health , Hamilton, Ontario, Canada Genoa Pharmaceuticals Inc....
BioCentury | Nov 12, 2012
Financial News

Genoa Pharmaceuticals completes venture financing

Genoa Pharmaceuticals Inc. , San Diego, Calif. Business: Pulmonary Date completed: 11/8/12 Type: Venture financing Raised: $1.2 million WIR Staff...
Items per page:
1 - 8 of 8
BioCentury | Feb 1, 2018
Financial News

EdRIP considering split from Rothschild

...Banque. The firm declined to comment. Last May, EdRIP backed idiopathic pulmonary fibrosis (IPF) company Genoa Pharmaceuticals Inc....
BioCentury | May 19, 2017
Finance

Breathe in, cash out

...By installing a proven CEO and ponying up sufficient cash to clear Phase II development, Genoa Pharmaceuticals Inc....
BioCentury | May 17, 2017
Financial News

Genoa's series A brings in $62M

...Pulmonary play Genoa Pharmaceuticals Inc. (Seattle, Wash.) raised $62 million in a series A round on May 15...
...Investment Partners . Also participating were Novo A/S , RiverVest Venture Partners and TPG Biotech. Genoa Pharmaceuticals Inc....
BioCentury | May 15, 2017
Financial News

Genoa's series A brings in $62M

...Pulmonary play Genoa Pharmaceuticals Inc. (Seattle, Wash.) said it raised $62 million in a series A financing led...
BioCentury | Aug 18, 2014
Clinical News

GP-101 regulatory update

...BioCentury, July 14). Pirfenidone is a small molecule inhibitor of proinflammatory cytokines and pro-fibrotic cytokines. Genoa Pharmaceuticals Inc....
BioCentury | Jun 17, 2013
Clinical News

Genoa Pharmaceuticals preclinical data

...rights in South Korea and Taiwan and markets it as Pirespa for IPF in Japan. Genoa Pharmaceuticals Inc....
BioCentury | Mar 21, 2013
Targets & Mechanisms

Understanding fibrosis

...University , ultimately wanted to see studies of pirfenidone plus fasudil. Kolb is collaborating with Genoa Pharmaceuticals Inc....
...Kasei Pharma Corp. , Tokyo, Japan Firestone Institute for Respiratory Health , Hamilton, Ontario, Canada Genoa Pharmaceuticals Inc....
BioCentury | Nov 12, 2012
Financial News

Genoa Pharmaceuticals completes venture financing

Genoa Pharmaceuticals Inc. , San Diego, Calif. Business: Pulmonary Date completed: 11/8/12 Type: Venture financing Raised: $1.2 million WIR Staff...
Items per page:
1 - 8 of 8